Shire Plc ADS, Each Representing Three Ordinary Shares Stock Price - SHPG

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Shire Plc ADS, Each Representing Three Ordinary Shares SHPG NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00 0.00% 179.20 0.00 0.00 0.00 179.20 20:00:00
Bid Price Ask Price Spread Spread % News
166.00 181.75 15.75 8.67% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.00 USD

Shire Plc ADS, Each Representing Three Ordinary Shares Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 54.77B 305.65M $ 4.27B 14.01 11.40 305.65M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ 0.92 0.51% - -

more financials information »

Shire Plc ADS, Each Representing Three Ordinary Shares News

Loading Messages....

Latest SHPG Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical SHPG Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week0000.0000---
1 Month0000.0000---
3 Months0000.0000---
6 Months0000.0000---
1 Year0000.0000---
3 Years0000.0000---
5 Years0000.0000---

Shire Plc ADS, Each Representing Three Ordinary Shares Description

Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.


Your Recent History
NASDAQ
SHPG
Shire Plc ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.